Hubert Orfeuvre
Hôpital Saint-Jacques(FR)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Ovarian cancer diagnosis and treatment, Breast Cancer Treatment Studies, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer(2003)307 cited
- → Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial(2009)298 cited
- → Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens(2006)196 cited
- → HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group(2003)109 cited
- → Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial(2006)105 cited
- → Oral vinorelbine: Feasibility and safety profile(2001)48 cited
- → A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study(2007)46 cited
- → Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma(1998)43 cited
- → Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma(2012)35 cited
- → Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial(2012)33 cited